Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
147M
-
Number of holders
-
928
-
Total 13F shares, excl. options
-
128M
-
Shares change
-
+1.09M
-
Total reported value, excl. options
-
$29.8B
-
Value change
-
+$285M
-
Put/Call ratio
-
1.19
-
Number of buys
-
390
-
Number of sells
-
-423
-
Price
-
$231.82
Significant Holders of BIOGEN INC. - Common Stock (BIIB) as of Q2 2024
1,079 filings reported holding BIIB - BIOGEN INC. - Common Stock as of Q2 2024.
BIOGEN INC. - Common Stock (BIIB) has 928 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 128M shares
of 147M outstanding shares and own 87.25% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (16.6M shares), PRIMECAP MANAGEMENT CO/CA/ (16.3M shares), BlackRock Inc. (14.5M shares), STATE STREET CORP (7.1M shares), T. Rowe Price Investment Management, Inc. (5.68M shares), WELLINGTON MANAGEMENT GROUP LLP (5.17M shares), JPMORGAN CHASE & CO (4.71M shares), GEODE CAPITAL MANAGEMENT, LLC (3.57M shares), NORGES BANK (2.08M shares), and PRICE T ROWE ASSOCIATES INC /MD/ (2.01M shares).
This table shows the top 928 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.